Recent Updates
Recently added Catalysts
RLAY

Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event

Key Takeaway: CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced registration is
Price reaction · baseline $14.33 (2022-06-15 close) · hit after-hours · clean, no other RLAY news in the window
day 0 close
+2.7%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+284%
120-day peak, hindsight
Typical move
11.8%
average across 6 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
RLY-8161
Phase 1 · Advanced NRAS-Mutant Melanoma

Full Press Release Details

CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced registration is open for the virtual analyst and investor event on June 27, 2022 from 8:00 a.m. to 9:00 a.m. ET.
The virtual analyst and investor event will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available following the event.
About Relay Therapeutics
Last updated: Jun 16, 2022